← DexCom overview

DexCom vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DexCom Inc (DXCM)

Q3 2026
▲3▼1

DexCom gains on FDA clearance, strong Q2, and expanded coverage

  • FDA clears Stelo for young children The FDA cleared DexCom's Stelo biosensor for children aged 2 and up, opening a new market and supporting the stock.

    This is a new regulatory win that expands the addressable market.

  • Q2 revenue up 13%, guidance raised Q2 revenue rose 13% to $1.31 billion, leading DexCom to raise its 2026 revenue and margin guidance, a sign of strong business momentum.

    This is a new financial update that directly boosts investor confidence.

  • Investor Day and G7 rollout lift shares DexCom's Investor Day sent shares up 25%, and the G7 15 Day rollout progressed, with major PBM coverage now reaching over 7 million non-insulin Type 2 patients.

    These are new events that drove the stock higher during the quarter.

  • Abbott competition intensifies Abbott's FreeStyle Libre topped $2 billion in Q2 sales, and the FDA approved Abbott's Libre Duo, the first U.S. wearable tracking both glucose and ketones, potentially pressuring DexCom's pricing and market share.

    This is a new competitive threat that could weigh on DexCom's future growth.

August 2026
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

Latest
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

July 2026
▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

Danaher Corporation (DHR)

Q3 2026
▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

  • Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.

    The acquisition is the biggest new event and main reason for the stock's decline.

  • Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.

    This guidance cut directly impacts investor expectations and the stock's valuation.

  • Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.

    The miss highlights execution risks and weighs on sentiment.

  • Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.

    These positives show underlying business strength and innovation, providing a counterweight to the negatives.

July 2026
▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

  • Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.

    The acquisition is the biggest new event and main reason for the stock's decline.

  • Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.

    This guidance cut directly impacts investor expectations and the stock's valuation.

  • Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.

    The miss highlights execution risks and weighs on sentiment.

  • Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.

    These positives show underlying business strength and innovation, providing a counterweight to the negatives.

Latest
▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

  • Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.

    This is the main new negative event that directly answers why DHR is moving right now.

  • Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.

  • Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.

    This explains the nuance behind the revenue miss and why the stock reaction may be overdone.

  • Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.

    This provides a potential positive catalyst and shows analyst views on valuation after the decline.

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

  • Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.

    This is the main new event that caused the stock to drop over 10% this period.

  • Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.

    This explains the specific reason behind the guidance cut and the stock's decline.

  • Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a key positive from the quarter that contrasts with the negative reaction.

  • Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.

    This provides a counterweight to the negative news and suggests the stock may rebound.

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

  • Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.

    Explains the main reason DHR is down this year and the key overhang on the stock.

  • Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.

    Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.

  • Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.

    Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.

  • Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.

    Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.

© 2026 MarketIVWhy